Amifostine in clinical oncology: current use and future applications.
Koukourakis MI.
Anticancer Drugs · review; journal article · DOI 10.1097/00001813-200203000-00001 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för amifostine. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
38 hitsEffects of amifostine on liver oxidative stress caused by cyclophosphamide administration to rats.
Stankiewicz A, Skrzydlewska E, Makieła M.
Drug Metabol Drug Interact · journal article · DOI 10.1515/dmdi.2002.19.2.67Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F, Zhang J, Russell L, Oster W, Sauer R.
J Clin Oncol · clinical trial, phase iii; comparative study; clinical trial; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1200/jco.2000.18.19.3339Amifostine, a reactive oxigen species scavenger with radiation- and chemo-protective properties, inhibits in vitro platelet activation induced by ADP, collagen or PAF.
Porta C, Maiolo A, Tua A, Grignani G.
Haematologica · comparative study; journal articleAmifostine: mechanisms of action underlying cytoprotection and chemoprevention.
Grdina DJ, Kataoka Y, Murley JS.
Drug Metabol Drug Interact · research support, u.s. gov't, p.h.s.; journal article · DOI 10.1515/dmdi.2000.16.4.237The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V, Giles FJ.
Haematologica · review; journal articleAmifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J.
J Clin Oncol · clinical trial; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1200/jco.1996.14.7.2101Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.
Spencer CM, Goa KL.
Drugs · review; journal article · DOI 10.2165/00003495-199550060-00008